Introduction
============

V-type proton (H^+^) ATPase (v-ATPase) is a multimeric complex that acts as an ATP-dependent proton pump. V-ATPase is composed of a peripheral V~1~ domain that hydrolyses ATP and an integral V~0~ domain that translocates protons by a rotary mechanism. V-ATPase is responsible for membrane trafficking processes such as receptor-mediated endocytosis, intracellular trafficking of lysosomal enzymes, and acidification of intracellular organelles in all eukaryotic cells ([@awy092-B13]; [@awy092-B7]). Despite the ubiquitous role in pH homeostasis and intracellular signalling pathways, the v-ATPase complex is expressed at high levels in neurons where it plays additional and unique roles in neurotransmitter loading into synaptic vesicles and in regulating synaptic transmission ([@awy092-B37]; [@awy092-B5]).

In humans, a redundant set of subunits is encoded by 22 autosomal genes, allowing the composition of diverse v-ATPase complexes with specific properties and tissue expression. Among these, seven have been associated with human disease ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Six subunits have been related to recessive disorders, including distal renal tubular acidosis and hearing loss (ATP6V1B1 and ATP6V0A4) ([@awy092-B24]; [@awy092-B48]; [@awy092-B49]), osteopetrosis with macrocephaly, progressive deafness, blindness, hepatosplenomegaly, and severe anaemia (ATP6V0A3) ([@awy092-B14]; [@awy092-B28]), and cutis laxa, a systemic disease with severe neurological impairment featuring structural brain abnormalities, profound delay, and seizures (ATP6V0A2, ATP6V1E1 and ATP6V1A) ([@awy092-B27]; [@awy092-B12]; [@awy092-B53]). Two allelic dominant disorders, Zimmermann-Laband syndrome type 2, featuring facial dysmorphisms and intellectual disability ([@awy092-B29]) and a form of congenital deafness with anonyochia, have also been described (ATP6V1B2) ([@awy092-B58]).

Through whole exome sequencing of 1444 patients with developmental encephalopathies and epilepsy, we identified in four patients heterozygous *de novo* missense mutations in *ATP6V1A* (p.Pro27Arg, p.Asp100Tyr, p.Asp349Asn, p.Asp371Gly), all involving highly evolutionarily conserved residues in functionally relevant regions of the molecule. Functional analysis conducted for the p.Asp100Tyr and p.Asp349Asn mutations demonstrated a loss-of-function mechanism involving increased ATPase degradation and lysosomal defects for the former, and a gain-of-function mechanism consisting of increased acidification of intracellular organelles for the latter. In neurons, both ATP6V1A mutants caused a defect in neurite elongation, accompanied by a significant loss of excitatory synapses, suggesting a crucial and unexplored role of v-ATPase in neuronal development and synapse formation. We provide evidence that *de novo* heterozygous *ATP6V1A* mutations cause a developmental encephalopathy with epilepsy with a pathomechanism that involves the effects of v-ATPase in lysosomal homeostasis and neuronal connectivity. This study also demonstrates that *ATP6V1A* mutations can be disease causing at the heterozygous state, although previously described biallelic phenotypes are more severe.

Patients and methods
====================

Patients
--------

Exome studies were conducted in three cohorts, including patients of different ethnicities ([Supplementary Table 2A](#sup1){ref-type="supplementary-material"}), with developmental delay/intellectual disability and epilepsy of presumed genetic origin. The overall series consisted of 1444 probands, most of whom were part of a trios study. Patients were assigned to eight specific epileptic encephalopathy syndromes, plus a ninth subgroup of 'unclassified' epileptic encephalopathies with mixed seizure disorders that could not be assigned to a specific syndrome ([Supplementary Table 2B](#sup1){ref-type="supplementary-material"}). All four patients with *ATP6V1A* mutations belonged to the latter subgroup.

All participants to the study had signed an informed consent for research whole exome sequencing studies. The study was approved by the Paediatric Ethic Committee of the Tuscany Region, in the context of the DESIRE project (Seventh Framework Programme FP7; grant agreement n° 602 531).

Whole exome sequencing
----------------------

In 900 patients, whole exome sequencing was performed with the SureSelectXT Human All Exon v5 or v6 (Agilent Technologies). Captured libraries were sequenced using Illumina Hiseq 2500 (Illumina) with 101-base paired-end reads. Exome data processing, variant calling, and variant annotation were performed as previously described ([@awy092-B45]). In singleton probands exhibiting *de novo* mutations, parentage was confirmed by microsatellite analysis, as previously described ([@awy092-B45]). In 494 patients, whole exome sequencing was performed and analysed as previously described ([@awy092-B39]). In 50 additional patients, exons were captured from fragmented genomic DNA samples using the SureSelect Human All Exon v4 (Agilent Technologies), and paired-end 90-base massively parallel sequencing was carried out on an Illumina HiSeq 2000, according to the manufacturer's protocols (Illumina). In the latter group, bioinformatics analysis was carried out using an in-house developed pipeline. Sequencing reads passing quality filtering were aligned to the human reference genome (hg19) with Burrows-Wheeler Aligner (BWA) ([@awy092-B32]). The Genome Analysis Toolkit (GATK) ([@awy092-B34]) was used for base quality score recalibration, indel realignment, duplicate removal, and to perform SNP and INDEL discovery and genotyping across all samples simultaneously using variant quality score recalibration according to GATK Best Practices recommendations ([@awy092-B9]; [@awy092-B54]). For annotating and filtering data, the SNPeff program was used ([@awy092-B6]). The *de novo* variants were called using the DeNovoGear tool with a 0.8 threshold at the posterior probability of the most likely *de novo* genotype configuration ([@awy092-B42]). All samples had a mean depth of target region covered at 112× and \>97% of bases in the consensus coding sequences covered by at least 20 reads. We excluded variants with minor allele frequency (MAF) \>1% in either the 1000 Genomes Project (1000g) or the Exome Aggregation Consortium (ExAC v0.3) databases.

In patients carrying *ATP6V1A* variants, we excluded *de novo* or recessive (MAF \< 1%) variants in the well-established genes for epileptic encephalopathies (listed in [Supplementary Table 3](#sup1){ref-type="supplementary-material"}) and submitted for validation and segregation testing by Sanger sequencing of candidate *de novo* variants that were predicted to alter protein function (non-synonymous, stop-gain, stop-loss, frameshift, and splice-junction mutations).

We evaluated whether the *ATP6V1A* human protein-coding gene is likely to harbour disease-causing mutations using different gene-level prediction tools including the ExAC (Exome Aggregation Consortium) constraint metrics ([@awy092-B30]), the residual variation intolerance score (RVIS; based on ExAC v2 release 2.0) ([@awy092-B41]) and the gene damage index (GDI) ([@awy092-B22]). Furthermore, to improve the use of existing variant-level methods such as the Combined Annotation Dependent Depletion (CADD) score ([@awy092-B26]) and test the four missense substitutions we identified in *ATP6V1A*, we also used the mutation significance cut-off (MSC) server ([@awy092-B21]), a quantitative approach that provides gene-level and gene-specific phenotypic impact cut-off values.

We evaluated mutations' pathogenicity for the four *ATP6V1A* variants through *in silico* prediction using the dbNSFP database (v3.0a), which provides functional prediction scores on more than 20 different algorithms (<https://sites.google.com/site/jpopgen/dbNSFP>). To assess the effects of the four missense *ATP6V1A* substitutions, we used both the dbNSFP ensemble rank scores MetaSVM and MetaLR ([@awy092-B33]). In addition, we used the scores obtained from Revel ([@awy092-B18]), M-CAP ([@awy092-B23]) and Eigen ([@awy092-B19]), three different bioinformatics tools to evaluate the pathogenicity of rare variants.

We performed conservation analysis across species (orthologous sequences) using a multiple sequence alignment (MSA) of the ATP6V1A protein sequence. The MSA (MUSCLE algorithm) and the sequence logo consensus were generated by the Jalview software (<http://www.jalview.org>). Residues were coloured according to their physicochemical properties (Zappo colour scheme).

To evaluate if *de novo ATP6V1A* variants had ever been reported, either in affected individuals or controls, we interrogated the denovo-db database ([@awy092-B52]).

*ATP6V1A* gene *de novo* mutation enrichment analysis
-----------------------------------------------------

To assess whether in the 1444 probands cohort the *ATP6V1A* gene was enriched in missense *de novo* mutations, we used the freely available R package DenovolyzeR ([@awy092-B57]) and gene-specific mutation rates originally reported by [@awy092-B47]. The *ATP6V1A de novo* gene-specific *P*-value calculated by DenovolyzeR for missense variants was corrected for multiple testing (Bonferroni correction), according to the 19 618 genes for which mutation rates are available, and the number of tests (one test for the missense class). The genome-wide Bonferroni corrected *P*-value threshold at α = 0.05 for one test was 2.55 × 10^−6^ \[0.05/(1 × 19 168)\]. We carried out the *ATP6V1A de novo* mutation enrichment analysis in the overall cohort without any stratification using the RStudio software (rstudio.com).

To rule out that the four variants could have arisen by chance, we performed the chi-squared test with Yates correction for a 2 × 2 contingency table (patients carrying the variants/mutation negative patients versus controls carrying the variants/mutation negative controls) using the QuickCalcs tool (graphpad.com/quickcalcs/contingency1.cfm). For each variant, we carried out the test on exome data of our cohort and the Genome Aggregation Database (gnomAD) cohorts, both at large and through ethnicity-matched analysis.

Structural modelling
--------------------

We searched the crystal structure homologous to human ATP6V1A using the protein homology/analogy recognition engine, Phyre2 ([@awy092-B25]). We calculated the free energy change upon the Asp85Tyr mutation with the FoldX software (foldxsuite.crg.eu) using the crystal structure of the V~1~ domain from *Enterococcus hirae* v-ATPase in a nucleotide-bound state (PDB code 3VR6). The molecular structures were drawn using PyMOL (Schrödinger, New York, NY). Using the same Phyre2 server, we also obtained the alignment of human ATP6V1A and *Saccharomyces cerevisiae* A subunit primary sequences. The homology model was created using I-TASSER ([@awy092-B43]), with the A subunit of *S. cerevisiae* v-ATPase (PDB code 3J9T) as template.

*ATP6V1A* constructs
--------------------

We synthesized wild-type and mutant (p.Asp100Tyr and p.Asp349Asn) human *ATP6V1A* cDNAs *in vitro* and cloned in pLVX-IRES-mCherry vector by Biomatik. We performed Sanger sequencing of all constructs to check the correct inserts orientation and validate their sequence.

Cell culture and transfection
-----------------------------

Human embryonic kidney-derived 293T (HEK) cells were maintained at 37°C in a humidified 5% CO~2~ incubator in DMEM (Life Technologies) supplemented with 10% FBS, 2 mM [l]{.smallcaps}-glutamine and 1% Penicillin-Streptomycin. Cells were transfected with Lipofectamine 2000 (Life Technologies) according to the manufacturer's instructions. HEK cells were starved by medium withdrawal for 2 h. Lymphoblatsts were prepared by infecting lymphocytes obtained from patients and their parents with the Epstein-Barr virus (EBV) *in vitro* using standard protocols and maintained in RPMI 20% foetal bovine serum (FBS), 1 mM [l]{.smallcaps}-glutamine and 10 mM [d]{.smallcaps}-glucose. Primary cortical neurons were prepared from embryonic Day 18 brains of Sprague Dawley rats as previously described ([@awy092-B55]). Neurons were transfected using Lipofectamine® 2000 at 7 or 14 days *in vitro* (DIV) and analysed 3 days after transfection.

Western blotting
----------------

Protein lysates from HEK, lymphoblast and neuronal cultures were extracted in lysis buffer \[50 mM Tris (pH 7.5), 150 mM NaCl, 0.1% SDS, 1% Nonidet P40, 0.2 mM phenylmethylsulfonyl fluoride, 2 μg/ml pepstatin, and 1 μg/ml leupeptin\] and then separated by SDS-PAGE and assayed by immunoblotting with the following primary antibodies: anti-ATP6V1A (1:1000; \#ab137574, Abcam), anti-ATP6V1B2 (1:2000; \#ab73404, Abcam), anti-LAMP1 (1:1000; \#ab24170, Abcam), anti-EEA1 (1:5000; \#610457, BD Bioscience), LC3B (1:1000; \#7543, Sigma-Aldrich), p62 (1:1000, \#P0067, Sigma-Aldrich), anti-GAPDH (1/1000; \#SC-25778, Santa Cruz Biotechnology), anti-VAMP2 (1:1000; \#104202; Synaptic Systems); anti-V-GLUT1 (1:1000; \#135304, Synaptic Systems) anti-PSD95 (1:1000; \#SC-32290, Santa Cruz Biotechnology).

Degradation assay
-----------------

HEK cells were transfected with ATP6V1A wild-type, ATP6V1A Asp349Asn or ATP6V1A Asp100Tyr and treated with 10 µg/ml of cycloheximide (C4859, Sigma-Aldrich) 24 h after transfection. Cells were lysed at different times after cycloheximide addition and analysed by western blotting. Protein level is expressed with respect to ATP6V1A content in the cells collected at time zero and treated with vehicle (DMSO).

Immunocytochemistry and fluorescence microscopy
-----------------------------------------------

Transfected primary cortical neurons or HEK cells were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS), permeabilized in 0.1% Triton™ X-100, blocked with 2% FBS/0.05% Tween-20 in PBS and incubated with the various antibodies in blocking solution. Samples were mounted in ProLong® Gold antifade reagent with DAPI (\#P36935, Thermo-Fisher Scientific). Capture of confocal images was performed using a laser scanning confocal microscope (SP5, Leica) with a 40× or 63× oil-immersion objective. For LAMP1 (1:200, \#L1418 Sigma-Aldrich) and EEA1 (1:500; \#610457, BD Bioscience), ATP6V1B2 (1:200, \#SAB1405501 Sigma-Aldrich) and LC3B (1:200, \#2775 Cell Signalling) labelling, each image consisted of a stack of images taken through the *z*-plane of the cell. The co-localization of ATP6V1B2 and LC3B signals was analysed using the ImageJ intensity correlation analysis plugin to calculate Pearson's correlation coefficient. For LysoTracker® Deep Red (Molecular Probes/Life Technologies) experiments, HEK cells were incubated with 200 nM LysoTracker® for 1 h, whereas neurons were incubated with 50 nM LysoTracker® for 30 min, at 37°C in culture medium, immediately fixed and analysed within 12 h. Images were taken at either epifluorescence (Olympus 1X81) or confocal (SP5, Leica) microscope in a single plane not to fade the fluorescent signal. Settings were kept the same for all acquisitions within each experiment.

Measurement of endo-lysosomal pH
--------------------------------

Endo-lysosomal pH was measured using a ratiometric pH indicator dye, LysoSensor™ Yellow/Blue dextran (Molecular Probes/Life Technologies), a dual excitation dye that allows pH measurement in endocytic organelles independently of dye concentration. Lymphoblasts (4 × 10^6^) were incubated for 3 h at 37°C with 0.5 mg/ml of LysoSensor™ Yellow/Blue dextran in culture medium. Cells were divided into five samples, four to perform the calibration curve and one for the measurements. To obtain a pH calibration curve, cells were resuspended with MES calibration buffer solution (5 mM NaCl, 115 mM KCl, 1.2 mM MgSO~4~ and 25 mM MES, pH ranging from 3.7 to 7.6) containing 10 µM monensin (Sigma-Aldrich) and 10 μM nigericin (Sigma-Aldrich). For the pH measures, cells were resuspended in MES calibration buffer solution pH 7.7 in the absence of ionophores. Emission scans were collected at 450 nm and 528 nm with the Luminescence Spectrometer LS 50 (Perkin Elmer), using excitation at 360 nm and emission/excitation bandwidths set to 4 nm. Calibration data (ratio 450/528) were fitted to a linear regression with the software GraphPad Prism5 and the sample ratios converted into absolute pH values by interpolation in the calibration function.

Sholl analysis
--------------

Neurons were plated at low density (80 cells/mm^2^), transfected at 7 DIV and analysed at 10 DIV. For analysis, neurons were fixed in 4% PFA, in PBS and decorated with βIII tubulin antibody (1:1000, \#MMS-435P Covance) followed by Alexa Fluor® 488 secondary antibody to unequivocally distinguish neuronal cells. The extent of neurite arborization was evaluated using Sholl analysis as previously described ([@awy092-B11]). Concentric circles with radii increasing at regular 10-μm steps were centred to the cell body and the number of intersections was automatically evaluated with the ImageJ/Sholl analysis plug-in.

Synapse quantification
----------------------

Neurons, plated at low density as described above, were either transfected at 14 DIV and analysed at 17 DIV or treated at 17 DIV with 200 nM leupeptin for 3 h (\#EI8, MerckMillipore; [@awy092-B15]). To measure excitatory synapses, neurons were labelled with anti-V-GLUT1 (1/500, \#135304; Synaptic Systems) and anti-Homer1 (1/200, \#160011; Synaptic Systems) antibodies. Confocal images were acquired with a laser scanning confocal microscope (SP5 Upright, Leica) with a 40× oil-immersion objective. Each image consisted of a stack of images taken through the *z*-plane of the cell. Confocal microscope settings were kept the same for all scans in each experiment. The co-localization analysis was performed by evaluating the labelling of the VGLUT1/Homer1 synaptic protein couples. Co-localization puncta with areas of 0.1--2 µm^2^ were considered *bona fide* synaptic boutons. Synaptic boutons along Cherry-positive neurites were manually counted on 30 µm puncta starting from the cell body.

Results
=======

Identification of *ATP6V1A* mutations
-------------------------------------

Trio-based whole exome sequencing studies revealed *de novo* mutations in *ATP6V1A* (MIM 607 027; RefSeq accession number NM_001690.3), encoding the ATPase H^+^ transporting V~1~ subunit A in three patients \[Patient 1: c.298G \> T (p.Asp100Tyr); Patient 2: c.1045G \> A (p.Asp349Asn); and Patient 4: c.80C \> G (p.Pro27Arg)\]. A subsequent search for *ATP6V1A* variants in whole exome sequencing data obtained from singleton patients, identified an additional patient carrying a *de novo* heterozygous *ATP6V1A* variant \[Patient 3: c.1112A \> G (p.Asp371Gly)\]. Patients 1--3 were identified via an ongoing collaboration matching exome data generated in Europe by the DESIRE project on rare developmental/epileptic encephalopathies (<http://epilepsydesireproject.eu>) with those of a comparable cohort in Japan. Patient 4 was subsequently identified through DESIRE dissemination activities, after preliminary data on the first three patients were made available in the project website. We also screened for *ATP6V1A* inherited variants with a frequency \<1% in the 1000 Genomes Project (1000g) or in the Exome Aggregation Consortium (ExAC) databases, both in cases of homozygous recessive or compound heterozygous state.

None of the *de novo ATP6V1A* identified mutations was observed in the 1000g, ExAC, gnomAD or dbSNP (build 147) databases. We confirmed the mutations and their *de novo* nature on genomic DNA of probands and parents by Sanger sequencing. Patient 3 parentage was confirmed using 12 microsatellite markers.

All four highly functionally relevant *de novo* mutations caused missense substitutions at evolutionarily conserved amino acid positions ([Fig. 1](#awy092-F1){ref-type="fig"}) and were predicted to be damaging by *in silico* methods ([Supplementary Table 4A](#sup1){ref-type="supplementary-material"}). ExAC constraint metrics indicated that *ATP6V1A* has fewer variants than expected and is intolerant both to loss-of-function (pLI = 0.99) and missense variants (Z-score = 3.03). The RVIS (RVIS score −0.7; RVIS percentile 20.93%) and the GDI (GDI score 22.7; GDI_Phred 0.76) scores also highlight *ATP6V1A* intolerance to variations. Finally, the MSC damage prediction (99% confidence interval) tool highlights the highly damaging impact the p.Pro27Arg, p.Asp100Tyr, p.Asp349Asn, and p.Asp371Gly substitutions have on the ATP6V1A protein, according to the MSC CADD corrected scores ([Supplementary Table 4B](#sup1){ref-type="supplementary-material"}).

![**Multiple sequence alignment and sequences logo.** Multiple sequence alignment between human ATP6V1A and orthologous sequences. Residues were coloured according to their physico-chemical properties (Zappo colour scheme). Residues affected by the missense substitutions are indicated by black arrows.](awy092f1){#awy092-F1}

To explore pathogenicity of the four variants further, we performed gene-specific *de novo* mutation enrichment analysis and a variant-specific chi-squared test with Yates correction for a 2 × 2 contingency table. The *ATP6V1A* missense *de novo* mutations enrichment analysis performed with DenovolyzeR (*n* = 1444, *de novo* mutations observed = 4, *de novo* mutations expected = 0.1, enrichment 79) reached genome-wide statistical significance (*P*-value of 2.63 × 10^−7^; Bonferroni correct threshold *P*-value 2.55 × 10^−6^). All four variants reached significant values (*P* \< 0.0001) in the chi-squared test performed using the 123 136 gnomAD exomes as control ([Supplementary Table 5A](#sup1){ref-type="supplementary-material"}). Performing the same analysis matching the four mutations versus ethnically matched subpopulations, all mutations maintained significant values ([Supplementary Table 5B--E](#sup1){ref-type="supplementary-material"}). These data suggest that the *ATP6V1A* mutations did not occur by chance in the cohort studied.

The denovo-db returned only five *de novo* hits (three intronic and two missense substitutions) in *ATP6V1A*. The two missense substitutions were p.Asp11Asn, identified in a male with autism spectrum disorder ([@awy092-B20]), and p.Pro249Arg identified in another male with a severe developmental disorder ([@awy092-B35]). These two missense substitutions, however, have not been subjected to orthogonal validation and should therefore be considered as 'potential' *de novo* variants. These data further highlight how rare *de novo* mutations are in the *ATP6V1A* gene.

Clinical findings
-----------------

Clinical, EEG and MRI findings observed in the four patients are summarized in [Table 1](#awy092-T1){ref-type="table"} and presented in detail in the [Supplementary material](#sup1){ref-type="supplementary-material"}. In brief, early manifestations, observed in all patients, were developmental delay and febrile seizures, evolving in two patients to encephalopathy with profound delay, hypotonic/dyskinetic quadriparesis, intractable multiple seizure types and severe diffuse epileptiform EEG abnormalities (Patients 1 and 4) and to moderate delay with milder epilepsy and focal/multifocal EEG abnormalities in the other two (Patients 2 and 3). Table 1Summary of clinical features in four patients carrying *ATP6V1A* mutationsPatient1234Origin/sexCaucasian/FAsian/MCaucasian/FLatino/MAge at follow-up14 years8 years8 years11 years*ATP6V1A* mutationc.298G\>T (p.Asp100Tyr) *de novo*c.1045G\>A (p.Asp349Asn) *de novo*c.1112A\>G (p.Asp371Gly) *de novo*c.80C\>G (p.Pro27Arg) *de novo*Clinical diagnosisInfantile onset epileptic encephalopathyID/epilepsyID/epilepsyInfantile onset epileptic encephalopathyHead circumferenceAt birth: 32 cm = 3rd %ile (−1.9 SD); at 12 years: 44.5 cm ≤ 1st %ile (−7 SD): microcephalyAt birth: 33 cm = 10th %ile (−1.2 SD)UnknownAt 12 months: 43.5 cm = 1st %ile (−2.2 SD); at 11 years: 49 cm ≤ 1st %ile (−3.2 SD): microcephalyAge/symptoms at first  clinical presentation11 months, hypotonia, developmental delay, seizures1 month, developmental delay, jerky movement2 years 6 months, developmental delay, seizures7 months, hypotonia, developmental delayEpilepsy++++Age at seizure onset11 months2 years 10 months2 years 6 months11 monthsSeizures typesConvulsive seizures during fever at onset, then infantile spasms, tonic, focal clonic, focal occipitalConvulsive seizures during fever at onset, then focal occipitalConvulsive seizures during fever at onset, then generalized tonic-clonicConvulsive seizures during fever at onset, then spasms, tonic, clonic and myoclonicInterictal EEGSlow background, diffuse and multifocal epileptiform dischargesPosteriorly dominant, multifocal epileptiform dischargesAnteriorly predominant multifocal epileptiform dischargesSlow background, diffuse and multifocal epileptiform dischargesBrain MRIHypomyelination, mild brain and cerebellar atrophyNormal at 7 yearsNormal at 7 yearsMild atrophy at 1 years 5 months and 3 years 7 monthsClinical phenotype  at last follow-upProfound delay, non-verbal, no visual fixation, hypotonic/dyskinetic quadriparesis, non-ambulatory, early puberty (9 years).Moderate ID (FSDQ: 53), poor language, headache, amelogenesis imperfecta diagnosed at 3 years, optic atrophyModerate ID, poor language, mild dysmorphic features (wide forehead, deep set eyes, beaked nose), behavioural abnormalities with autistic traits, wide based gait, hypotoniaProfound delay, non-verbal, no visual fixation, coloboma of the iris, hypotonic/dyskinetic quadriparesis, non-ambulatory[^2]

Structural consideration of the v-ATPase mutations
--------------------------------------------------

We mapped the mutation sites of human ATP6V1A onto the crystal structure of the V~1~ domain from a prokaryotic homologue, *E. hirae* v-ATPase, in a nucleotide-bound state (PDB code 3VR6) ([@awy092-B3]). All the identified mutations fall into the A subunit of the V~1~ domain ([Fig. 2](#awy092-F2){ref-type="fig"}A).

![**Structural mapping of the missense mutations in the V-ATPase.** (**A**) *Left*: Crystal structure of the V~1~ domain from *E. hirae* v-ATPase in a nucleotide-bound state (PDB code 3VR6), viewed from the extracellular side (*top*) and the membrane plane (*bottom*), shown as the sphere representation. The A, B, D and F subunits are coloured in cyan, green, violet and brown, respectively, and residues at the mutation sites are coloured in red. The non-hydrolyzable ATP analogue ANP (phosphoaminophosphonic acid-adenylate ester) is depicted as orange sticks. *Right*: Magnified views of the mutation sites presented in the ribbon model. Pro12 and Asp85 are depicted as red sticks, and Arg89, which makes a salt bridge with Asp85, is shown as sticks with translucent spheres. Some side chains of hydrophobic residues around Arg89 are shown as translucent spheres, and magnesium ion and its coordinated water molecules are depicted as a purple sphere and small grey dots, respectively. Black dotted lines indicate hydrogen bonds. Amino acid numbers in parentheses correspond to those of human ATP6V1A. (**B**) Crystal structures of the A subunit from *E. hirae* (orange) and the cryo-EM structure of the A subunit from *S. cerevisiae* (cyan, PDB code 3J9T) V-ATPase. Mutation sites are shown as spheres and coloured in red for *S. cerevisiae* and blue for *E. hirae*.](awy092f2){#awy092-F2}

Pro12 (Pro27 in human ATP6V1A) resides in the type I β-turn that is a part of the interaction interface between subunits A and B. Since the substitution of a proline residue with an arginine residue affects the main-chain conformation of the β-turn, the mutation may perturb the A--B interaction ([Fig. 2](#awy092-F2){ref-type="fig"}A and B).

Asp85 (Asp100 in human ATP6V1A) makes a hydrogen bond with Arg89, a guanidium group that makes van der Waals contacts with adjacent hydrophobic side chains ([Fig. 2](#awy092-F2){ref-type="fig"}B). As a result, the side chain of Asp85 is closely surrounded by hydrophobic residues, and its replacement with a bulkier tyrosine residue quite likely causes steric hindrance and destabilizes the protein folding. This is supported by the FoldX calculation, which predicted a significant increase in free energy (about 13 kcal/mol) upon the Asp85Tyr mutation.

Asp329 (Asp349 in human ATP6V1A) is located near a nucleotide-binding site ([Fig. 2](#awy092-F2){ref-type="fig"}B) and its side chain is involved in water-mediated coordination with a magnesium ion, which plays a critical role in the ATPase activity ([Fig. 2](#awy092-F2){ref-type="fig"}B). Thus, the Asp329Asn mutation possibly impairs the catalytic function.

Asp351 (Asp371 in human ATP6V1A) is located at the interface among A, B and D subunits ([Fig. 2](#awy092-F2){ref-type="fig"}A). The D subunit rotates within the A3B3 core along with the ATP hydrolysis, and thus the rotation process may be affected by the Asp351Gly mutation. The mutation sites were also mapped on the cryo-EM structure of the human homologue v-ATPase from the eukaryotic *S. cerevisiae* (rotational state 1, PDB code 3J9T) ([@awy092-B59]). As shown in [Fig. 2](#awy092-F2){ref-type="fig"}B, the mapped mutation sites in the *S. cerevisiae* structure overlap with those of the *E. hirae*, suggesting that the predicted impact of the mutations on the prokaryotic structure is also valid for the eukaryotic orthologues.

Finally, we generated a homology model of human ATP6V1A ([Supplementary Fig. 1](#sup1){ref-type="supplementary-material"}) using *S. cerevisiae* A subunit as template, obtaining a high-confidence result (C-score 88% and TM-score 87%). The resulting structure shows a fold similar to the template (*cf*. [Supplementary Fig. 1](#sup1){ref-type="supplementary-material"} and [2B](#sup1){ref-type="supplementary-material"}), and the mutation sites are in the same locations of the *E. hirae* and *S. cerevisiae* structures.

Effects of *ATP6V1A* mutations on protein expression and stability
------------------------------------------------------------------

We addressed the impact of p.Asp349Asn and p.Asp100Tyr mutations on the ATP6V1A expression and stability by analysing HEK cells overexpressing ATP6V1A. Cells were transfected with vectors driving the expression of the wild-type or mutant variants in association with a Cherry fluorescent tag for identification. Immunocytochemistry of transfected cells coupled with quantitative western blot analysis showed a decreased expression of both ATP6V1A mutants that reached significance only for the p.Asp100Tyr variant, and no overt subcellular mislocalization of both p.Asp100Tyr and p.Asp349Asn mutants with respect to wild-type ATP6V1A ([Fig. 3](#awy092-F3){ref-type="fig"}A and B). The expression of the molecular partner, ATP6V1B2, was not modified either by p.Asp100Tyr or p.Asp349Asn mutation ([Fig. 3](#awy092-F3){ref-type="fig"}B). To investigate the stability of ATP6V1A protein, we performed a degradation assay by treating transfected HEK cells with the protein synthesis inhibitor cycloheximide for various times. Compared to the wild-type isoform, both mutant ATP6V1A isoforms were less stable, although degradation was significantly increased only for the p.Asp100Tyr variant ([Fig. 3](#awy092-F3){ref-type="fig"}C).

![**Impact of *ATP6V1A* mutations on protein expression and stability.** (**A**) Representative images of HEK cells transfected with vectors coding wild-type ATP6V1A (w.t.), Asp349Asn ATP6V1A (Asp349Asn) or Asp100Tyr ATP6V1A (Asp100Tyr) variants. ATP6V1A immunolabelling, DAPI nuclear stain and Cherry reporter fluorescence are shown. Scale bar = 10 µm. (**B**) Representative western blot (*left*) from HEK cells transfected as above and lysed 24 h after transfection. ATP6V1A and ATP6V1B2 intensities were quantified by densitometric analysis with respect to GAPDH intensity (*right*). Data are means ± standard error of the mean (SEM) from five independent experiments. \**P \<*0.05 versus wild-type; Kruskall-Wallis/Dunn's tests. (**C**) *Left*: Representative western blots of HEK cell lysates stained with anti-ATP6V1A antibody and anti-GADPH as loading control. Cells were transfected with wild-type, Asp349Asn or Asp100Tyr ATP6V1A variants and incubated with cycloheximide for 2, 4, 8, 24 h or vehicle (DMSO; 24 h) as a control (--). *Right*: Densitometric analysis of ATP6V1A intensity with respect to GADPH expressed in percent of control samples without cycloheximide. Data are means ± SEM from four independent experiments. The areas under the respective curves were compared using the Kruskal-Wallis/Dunn's tests. \**P \<*0.05 versus wild-type. (**D**) Representative western blot from lymphoblast lysates (30 μg) of patient affected by the Asp349Asn mutation (proband) and the healthy mother. (**E**) Representative western blot from lymphoblast lysates (30 μg) of patient affected by the Asp100Tyr mutation (proband) and the healthy mother. In **D** and **E**, ATP6V1A and ATP6V1B2 intensity were quantified by densitometric analysis with respect to GADPH. Data are means ± SEM from four independent experiments. \**P \<*0.05; Mann Whitney U-test.](awy092f3){#awy092-F3}

We next asked whether these findings could also be observed in patients' cells. To this end, we analysed the expression of endogenous ATP6V1A protein in patients' lymphoblasts and compared it with the respective healthy parents' cells ([Fig. 3](#awy092-F3){ref-type="fig"}D and E). While the expression of ATP6V1A and ATP6V1B2 was not modified in Asp349Asn proband's cells with respect to his healthy mother's cells, a significant decrease of ATP6V1A, but not ATP6V1B2, expression was observed in Asp100Tyr proband's cells. These data are in full agreement with the structural analysis prediction of a folding defect in the p.Asp100Tyr mutant ([Fig. 2](#awy092-F2){ref-type="fig"}A) that may enhance its degradation.

*ATP6V1A* mutations result in lysosomal abnormalities
-----------------------------------------------------

To examine the impact of the p.Asp349Asn and p.Asp100Tyr mutations in the regulation of pH homeostasis, we used the LysoTracker® probe to qualitatively evaluate intracellular acidic organelles in HEK cells overexpressing either pathogenic or wild-type ATP6V1A variants. Interestingly, the p.Asp349Asn mutant increased, while the p.Asp100Tyr mutant decreased, LysoTracker® fluorescence intensity ([Fig. 4](#awy092-F4){ref-type="fig"}A). The LysoTracker® signal monitors both the actual pH of acidic organelles, namely endosomal and lysosomal compartments, and their relative abundance within the cell. Thus, we analysed in parallel the expression of the endosomal and lysosomal markers, EEA1 and LAMP1, respectively. Whereas EEA1 expression was unaltered in HEK cells expressing wild-type ATP6V1A or either pathogenic variants, the p.Asp100Tyr mutant was associated with a significant decrease of LAMP1 expression evaluated by both single cell immunocytochemistry ([Fig. 4](#awy092-F4){ref-type="fig"}B) and western blotting ([Supplementary Fig. 2A](#sup1){ref-type="supplementary-material"}). The data suggest that the p.Asp349Asn mutant exacerbates the acidic pH of intracellular organelles, while the p.Asp100Tyr mutant leads to a decreased expression of LAMP1-positive lysosomal structures. Lysosomes fuse with phagosomal and autophagosomal structures to generate autolysosomes and v-ATPase also acidifies autolysosomal organelles. We therefore investigated whether pathogenic *ATP6V1A* variants affect v-ATPase translocation to LC3-positive phagosomal structures. To this aim, we measured the co-localization between the v-ATPase subunit ATP6V1B2 and LC3 in HEK cells expressing wild-type ATP6V1A or either pathogenic variant. Both p.Asp100Tyr and p.Asp349Asn resulted in a decreased co-localization coefficient with respect to wild-type ATP6V1A ([Fig. 4](#awy092-F4){ref-type="fig"}C). However, the v-ATPase translocation induced by cell starvation was slightly impaired by p.Asp100Tyr and substantially unaffected by p.Asp349Asn ([Fig. 4](#awy092-F4){ref-type="fig"}C). No significant changes in LC3II/LC3I ratio and p62 accumulation were observed in both experimental groups ([Supplementary Fig. 2B](#sup1){ref-type="supplementary-material"}). These data suggest a significant impact of both mutations on the recruitment of the v-ATPase to LC3-positive autolysosomal structures, with slightly impaired autophagic flux only for Asp100Tyr.

![**Effects of *ATP6V1A* mutations on endo-lysosomal markers and v-ATPase recruitment to autophagosomes.** (**A**) *Left*: Representative images of HEK cells transfected with wild-type ATP6V1A (w.t.), Asp349Asn ATP6V1A (Asp349Asn) or Asp100Tyr ATP6V1A (Asp100Tyr) variants and incubated with LysoTracker® (200 nM, 1 h). *Right*: LysoTracker® fluorescence intensity was quantified in 38 (wild-type), 41 (Asp349Asn) and 45 (Asp100Tyr) cells from three independent experiments. Individual data and means ± SEM are shown. \**P \<*0.05, \*\*\*\**P \<*0.0001 versus wild-type; Kruskall-Wallis/Dunn's tests. (**B**) Representative images and densitometric quantification from HEK cells transfected as above and immunolabelled with LAMP1 (*left*) or EEA1 (*right*). Histograms show quantification of signal intensity. Data are means ± SEM of 24--33 cells per experimental condition, from three independent experiments. \*\**P \<*0.001 versus wild-type Kruskall-Wallis/Dunn's tests. (**C**) Representative images from HEK cells transfected as above and immunolabelled with ATP6V1B2 and LC3B under control conditions or after starvation for 2 h. Graph shows the quantification of ATP6V1B2 and LC3B co-localization using ImageJ software to determine the Pearson's correlation coefficient. Data are means ± SEM of 30 cells per experimental condition. \**P \<*0.05 versus respective control; ^\#^*P \<*0.001 versus non-starved wild-type; ^§^*P \<*0.001 versus starved wild-type. Data were analysed by two-way ANOVA/Bonferroni's tests.](awy092f4){#awy092-F4}

To verify whether altered lysosomal pH and levels of lysosomal markers were also present in patients, we subjected patients' lymphoblasts to the same analysis. Experiments using the ratiometric pH probe LysoSensor™ Yellow/Blue dextran, revealed a significant reduction in endocytic organelle pH in the Asp349Asn patient's lymphoblasts when compared to his healthy mother's lymphoblasts, in the absence of any change in the expression of LAMP1 and EEA1 ([Fig. 5](#awy092-F5){ref-type="fig"}). Conversely, while the pH of endocytic organelles was not modified in the Asp100Tyr patient's lymphoblasts, a significant reduction in LAMP1 expression was observed ([Fig. 5](#awy092-F5){ref-type="fig"}). Taken together, these data suggest a gain-of-function effect for the p.Asp349Asn mutation, characterized by an increased proton pumping into intracellular organelles, and a loss-of-function effect for the p.Asp100Tyr mutation associated with defects in lysosomal compartments.

![**Effects of *ATP6V1A* mutations on intracellular organelle pH and endo-lysosomal markers in patients' cells.** (**A**) Quantification of endocytic organelle pH in lymphoblasts from patients (probands) bearing either p.Asp349Asn (red) or p.Asp100Tyr (blue) mutation and the respective healthy mothers (black). Individual data and means ± SEM of five to six independent measurements are shown. \**P \<*0.05; Wilcoxon matched pairs signed rank test. (**B**) Representative western blot from lymphoblast lysates (30 μg) as defined above. LAMP1, EEA1 and GADPH as loading control is shown. (**C**) LAMP1 and EEA1 immunoreactivities were quantified by densitometric analysis and normalized to GADPH. Data are means ± SEM from four independent experiments. \**P \<*0.05; Mann-Whitney U-test.](awy092f5){#awy092-F5}

*ATP6V1A* mutations impact on neuronal pH homeostasis and neuronal development
------------------------------------------------------------------------------

In view of the neurodevelopmental phenotype observed in the four patients carrying *de novo* heterozygous *ATP6V1A* mutations, we investigated whether the effects on lysosomal homeostasis observed in HEK cells and patient-derived lymphoblasts were recapitulated in neurons. To address this question, we transiently expressed ATP6V1A and the pathogenic mutants thereof in rat hippocampal neuronal cultures and evaluated intracellular acidic organelles by LysoTracker® staining at the neuronal soma. As shown in [Fig. 6](#awy092-F6){ref-type="fig"}A, neurons overexpressing p.Asp349Asn resulted in a significantly higher LysoTracker® staining as compared to wild-type ATP6V1A-expressing neurons. In contrast, p.Asp100Tyr ATP6V1A overexpression induced a significant loss of LysoTracker® staining. Thus, the expression of the two mutants in neurons precisely phenocopies the effects observed in cell lines, suggesting that such an alteration in pH and lysosomal homeostasis also occurs in brain cells.

![**Effect of *ATP6V1A* mutations on pH homeostasis, development and synaptic connectivity in primary hippocampal neurons.** (**A**) *Left*: Representative images of rat hippocampal neurons transfected with wild-type (w.t.), Asp349Asn (Asp349Asn) and Asp100Tyr (Asp100Tyr) ATP6V1A variants at 7 DIV and incubated with LysoTracker® (50 nM, 30 min) at 10 DIV. *Right*: LysoTracker® fluorescence intensity was quantified in 31 (wild-type), 28 (Asp349Asn) and 33 (Asp100Tyr) neurons from two independent preparations. Individual data and means ± SEM are shown. \**P \<*0.05, \*\**P \<*0.01 versus wild-type; Kruskall-Wallis/Dunn's tests. (**B**) *Left*: Representative neurite traces of 10 DIV neurons transfected as in **A**. *Right*: Sholl analysis of neurite arborization as a function of distance from the soma. Data are means ± SEM of 29--33 neurons for experimental group from three independent preparations. \*\**P \<*0.01 versus wild-type; Kruskall-Wallis/Dunn's tests. (**C**) *Left*: Representative images of hippocampal neurons transfected with wild-type ATP6V1A (w.t.), Asp349Asn ATP6V1A (Asp349Asn) or Asp100Tyr ATP6V1A (Asp100Tyr) variants (*top*) at 14 DIV and analysed at 17 DIV. White rectangles indicate proximal dendrites shown at high magnification (*bottom*). Synaptic boutons were identified by double immunostaining for VGLUT1 (blue) and Homer1 (green). The co-localization panels (col. points) highlight the double-positive puncta (black), marked by arrowheads, corresponding to *bona fide* synapses. The merge panels show positive puncta along transfected branches. Scale bar = 10 µm. *Right*: Quantitative analysis of synaptic puncta counted on 30-µm branches starting from the cell body. Data are means ± SEM of 27--28 neurons per experimental condition, from three independent preparations. \*\*\*\**P \<*0.0001 versus wild-type; two-way ANOVA/Bonferroni's tests.](awy092f6){#awy092-F6}

To investigate cellular correlates of the patients' neurodevelopmental delay and explore whether the defects in LysoTracker® signal have an impact on neuronal development, we transfected rat hippocampal neurons at 7 DIV and analysed neurite elongation at 10 DIV by Sholl analysis. The analysis revealed a similar and significant loss of neurite arborization for both p.Asp349Asn- and p.Asp100Tyr-expressing neurons, indicating that both pathogenic variants significantly affect the outgrowth and branching of neuronal processes during development ([Fig. 6](#awy092-F6){ref-type="fig"}B).

*ATP6V1A* mutations affect synapse formation in primary neurons
---------------------------------------------------------------

In developing neurons, neurite elongation is followed by synapse formation and stabilization. V-ATPase is a fundamental protein component of synaptic vesicles, where it allows neurotransmitter loading and regulates synaptic transmission ([@awy092-B51]; [@awy092-B50]). Moreover, acidic lysosomes have been recently described at excitatory postsynaptic sites ([@awy092-B15]; [@awy092-B40]). Accordingly, the expression of the v-ATPase V~1~ subunits, ATP6V1A and ATP6V1B2, was found to increase with *in vitro* neuronal maturation and synaptogenesis along with the expression of pre- and postsynaptic markers ([Supplementary Fig. 3A](#sup1){ref-type="supplementary-material"}).

To study the effects of ATP6V1A mutants on synapse formation, we transfected hippocampal neurons at 14 DIV and analysed synapse density at 17 DIV. Excitatory synaptic contacts were visualized by double immunostaining with the presynaptic marker VGLUT1 and the postsynaptic marker Homer1 to identify mature excitatory synapses unambiguously. Synapse counting at 30 µm distance from the cell body revealed a significant loss of excitatory synaptic connections for p.Asp349Asn and p.Asp100Tyr overexpressing neurons, suggesting that both pathogenic variants dramatically impair the formation and maintenance of excitatory synapses ([Fig. 6](#awy092-F6){ref-type="fig"}C). Similar effects on the density of excitatory synaptic contacts were observed after treatment of hippocampal neurons with the lysosomal enzyme inhibitor leupeptin ([Supplementary Fig. 3B](#sup1){ref-type="supplementary-material"}).

Discussion
==========

The phenotypic features observed in the four patients reported here can be typically described as developmental encephalopathy with epilepsy and subsumed as *ATP6V1A* encephalopathy, although a larger number of observations is necessary to reveal the whole phenotypic spectrum. However, gathering a large series may take a long time because *ATP6V1A* mutations are very rare, and have not emerged before in large cohorts with epileptic and developmental encephalopathies ([@awy092-B1]; [@awy092-B2]; [@awy092-B35]); we could only identify four cases through whole exome sequencing studies on 1444 probands from three continents. Querying the denovo-db, we found only two potential *de novo* variants in the coding regions of *ATP6V1A*, thus further highlighting the rarity of *de novo* variants in this gene. Pathogenicity of the *de novo* p.Pro27Arg, p.Asp100Tyr, p.Asp349Asn and p.Asp371Gly variants could be established based on their: (i) occurrence in four patients with a developmental encephalopathy with epilepsy, the genome-wide statistical significance for missense *de novo* mutations enrichment; (ii) absence from publicly available databases; (iii) causing substitutions at highly evolutionarily conserved amino acid positions; and (iv) predicted highly damaging consequences emerging from *in silico* methods and the high intolerance of the *ATP6V1A* gene to variations. Accordingly, structural modelling allowed to localize the mutated sites in regions of ATP6V1A responsible for either the proper folding of the subunit (p.Asp100Tyr), the interaction with the V~0~ B subunit (p.Pro27Arg) or the function of the v-ATPase complex (p.Asp349Asn, p.Asp371Gly).

As most causative variations occur with very low allele frequency within each gene and only account for a small fraction of epilepsy patients ([@awy092-B38]) sequencing large cohorts of patients, collected through large networks and gene-matching tools has higher chances to find multiple affected individuals carrying *de novo* mutations in the same gene(s) ([@awy092-B17]). This strategy can overcome the challenge to determine whether the candidate *de novo* mutations have a causal relationship with the disease or are found by chance. A statistical framework specifically developed to address this challenge ([@awy092-B47]), and successfully applied to developmental disorders in previous studies ([@awy092-B31]; [@awy092-B35]), has also proved instrumental to demonstrate that *ATP6V1A* reached genome-wide statistical significance for missense *de novo* mutations enrichment in our cohort.

The Online Mendelian Inheritance in Man (OMIM) catalogue contains 59 entries for early infantile epileptic encephalopathies featuring intellectual disability and epilepsy (<https://www.omim.org/entry/308350?search> = EIEE&highlight = eiee) ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}), caused by mutations in as many genes, and mentions that similar phenotypes are also observed in other genetic disorders, highlighting the extreme genetic heterogeneity underlying this category.

The many genes that have been associated with such complex developmental epilepsy conditions have revealed the pathogenic role of mutations affecting diverse molecular pathways that regulate ion channel functioning, membrane excitability, synaptic plasticity, neurotransmitter release, postsynaptic receptors, transporters, cell metabolism, and many formative steps in early brain development such as the proliferation and migration of neuronal precursors, dendritogenesis, synaptogenesis, cell and glial biology ([@awy092-B16]). Our experimental work on the p.Asp100Tyr and p.Asp349Asn missense substitutions indicates that *ATP6V1A* mutations cause functional defects in v-ATPase physiology with alterations of lysosomal homeostasis associated with abnormal neuritogenesis and synaptic density.

The main function of v-ATPase is proton transport and acidification of intracellular organelles, in particular lysosomes that have critical requirements for pH. The functional experiments performed on the p.Asp100Tyr mutation, causing the more severe phenotype, demonstrated an increased degradation with impaired expression of ATP6V1A and lower lysosomal abundance. This finding was also associated with decreased recruitment of v-ATPase by autophagosomes under basal and starvation conditions, suggesting a potential impairment of the autophagic flux, as recently described in patients with mutations in the accessory v-ATPase subunit *ATP6AP2* ([@awy092-B44]). Conversely, p.Asp349Asn, which was associated with a milder phenotype, resulted in decreased endo-lysosomal pH, with no effects on either expression of the mutant protein or lysosomal abundance, pointing to a gain-of-function effect. This variant slightly impairs v-ATPase translocation to autophagosomes under basal, but not starvation, conditions, suggesting that the formation of autolysosomes is preserved. These functional findings were supported by structural modelling results, predicting that the p.Asp100Tyr mutation decreases protein stability, whereas p.Asp349Asn affects the catalytic activity of v-ATPase.

When modelled in hippocampal neurons, these pathogenic mutations produced the same significant and divergent effects on lysosomal marker intensity and endo-lysosomal pH that were observed in cell lines and probands' lymphoblasts, reflecting their relevance for the CNS. Moreover, in primary neurons, both p.Asp100Tyr and p.Asp349Asn mutants induced significant and comparable defects in dendrite development and excitatory synapse formation. The neuronal phenotype of both mutants demonstrates a previously unexplored role of the v-ATPase in the processes of neuronal development and connectivity. Similarities in changes on synapse formation induced by the two tested mutations and by leupeptin, a known inhibitor of lysosomal function, suggest an important pathophysiological role of altered lysosomal homeostasis. This hypothesis is also supported by recent reports on novel roles of lysosomes at the synapse for the turnover of synaptic proteins, as well as for the plasticity of dendritic spines ([@awy092-B15]; [@awy092-B40]; [@awy092-B46]).

Although the precise molecular mechanisms through which the described *de novo* mutations result in a developmental encephalopathy with epilepsy remain to be clarified, we here propose that alteration in lysosomal homeostasis may represent a novel pathogenic mechanism for this aetiologically heterogeneous group of disorders. Further work is needed to clarify the role of v-ATPase in brain development and to precisely establish the cellular signalling pathways that can be altered by loss of lysosomal homeostasis.

It is often impossible to disentangle whether the developmental or epileptic component is more important in contributing to a patient's presentation. In the four patients described here, however, there was good correspondence between severity of epilepsy and overall neurodevelopmental impairment, which might suggest either a more severe brain dysfunction leading to both severe impairment and to the epileptic encephalopathy or a deleterious effect of early severe and long-lasting epilepsy on development.

Next generation sequencing studies have demonstrated that sporadic developmental disorders associated with epilepsy, once considered potentially recessive in nature, often arise from *de novo* mutations of dominant genes and that the same gene can be associated with a broader phenotypic spectrum than originally believed ([@awy092-B36]). Our findings clearly link the *ATP6V1A* gene with a dominant form of encephalopathy after two biallelic homozygous missense mutations of the same gene had been related in three individuals to cutis laxa, a rare, severe systemic disorder, leading to early death in one of the patients and featuring, in addition to generalized skin wrinkling, marked hypotonia, dysmorphic facial features, cardiac abnormalities, structural brain abnormalities and seizures ([@awy092-B53]). Although comparison between our patients and the three previously reported with biallelic *ATP6V1A* mutations is only partially feasible, there is evidence that biallelic mutations cause a more complex phenotype in which severe neurological manifestations are part of a multi-organ involvement. A number of additional genetic developmental disorders with epilepsy, including those related to *PRRT2* ([@awy092-B10]), *TBC1D24* ([@awy092-B4]), *RELN* ([@awy092-B8]) and *SLC2A1* ([@awy092-B56]) genes, have been associated with both autosomal dominant and more severe recessive phenotypes.
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